Compare JF & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JF | SNSE |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 12.2M |
| IPO Year | N/A | 2021 |
| Metric | JF | SNSE |
|---|---|---|
| Price | $1.00 | $9.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $72.50 |
| AVG Volume (30 Days) | 46.8K | ★ 55.1K |
| Earning Date | 09-19-2025 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,961,892.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.20 | N/A |
| 52 Week Low | $0.82 | $5.00 |
| 52 Week High | $1.38 | $18.35 |
| Indicator | JF | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 49.14 | 44.76 |
| Support Level | $0.90 | $8.72 |
| Resistance Level | $1.01 | $9.56 |
| Average True Range (ATR) | 0.06 | 0.73 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 47.74 | 34.29 |
J and Friends Holdings Ltd, formerly Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees, as well as by providing financing for these borrowers and earning installment service fees. The company earns wealth management services fees and commissions on financial products. The company generates the majority of its revenue from Wealth management service fees and others.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).